I.S.R.A.E.L. RIVASM.A.B.E.L. MERIDADionicia ZeballosCarlos Agustín León Román2026-03-222026-03-22202410.1016/j.ekir.2024.02.1050https://doi.org/10.1016/j.ekir.2024.02.1050https://andeanlibrary.org/handle/123456789/74986The practice of kidney transplantation enhances the quality of life and improves the rates of survivance in patients with chronical renal diseases. In the case of a kidney transplant with a living donor, different mechanisms are being sought to improve residual renal function. Preclinical studies have identified the upregulation of NAD+ as a potential strategy for the prevention and treatment of AKI (acute kidney injury). NAD+ is the final metabolized form of vitamin B3. A recent clinical study found that COVID-19-related AKI was associated with NAD+ biosynthetic impairment arising in the context of ischemic, inflammatory, or toxic kidney injury.enMedicineKidneyVitamin D and neurologyIntensive care medicinePhysiologyarticle